June 13, 2024

ASCO was one of 25 organizations to applaud the Supreme Court’s unanimous ruling reversing the Fifth Circuit’s decision in Alliance for Hippocratic Medicine et al. v FDA et al, on the grounds that the plaintiffs don’t have standing in their challenge concerning the use and availability of Mifepristone.

June 4, 2024

Twenty-nine studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, and online, May 31-June 4. 

June 3, 2024

New study findings suggest that docetaxel may be considered the preferred treatment for Black patients with early-stage breast cancer compared to paclitaxel. While the trial focused specifically on Black people, the results highlight the need to personalize therapy in order to minimize toxicity. Importantly, this study offers a blueprint for how to design and recruit for a study focusing on a minority or underserved patient population. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

June 2, 2024

According to a new study, adding belantamab mafodotin to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma was more effective at slowing disease progression or death compared to current standard-of-care bortezomib plus pomalidomide and dexamethasone. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago, Illinois. 

June 2, 2024

For patients with locally advanced esophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment before and after surgery improved survival when compared to chemoradiotherapy before surgery. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

June 2, 2024

Trastuzumab deruxtecan delays cancer growth for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer that has progressed following endocrine therapy, according to findings from a new phase III clinical trial. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

June 2, 2024

New research reinforces telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, providing comparable quality-of-life benefits. This research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago, Illinois. 

June 2, 2024

Results from a new study demonstrate that consolidation therapy—or treatment given for a short time after the initial treatment has stopped cancer growth—after chemoradiotherapy with durvalumab helps patients with limited-stage small-cell lung cancer (LS-SCLC) live longer when compared to the current standard-of-care treatment of chemoradiotherapy alone. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

June 2, 2024

Osimertinib improves progression-free survival in patients with unresectable  stage III EGFR-mutated NSCLC that has been treated with chemoradiotherapy and may be a new standard of care for this population. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

June 2, 2024

Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not a deep response to treatment, promises better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

June 2, 2024

Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery aimed at removing as much of their primary cancer as possible without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.  

June 1, 2024

The American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support and advocacy organization in cancer, will create one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org. The collaboration was unveiled as the global oncology community gathered to share and discuss the latest clinical cancer research transforming patient care at the 2024 ASCO Annual Meeting in Chicago.

June 1, 2024

A new study showed that BrECADD, a novel therapy combination, cured classic Hodgkin lymphoma more effectively and with fewer side effects than the established intensive chemotherapy regimen BEACOPP. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

May 31, 2024

For patients with previously untreated, advanced non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) mutation, treatment with the ALK tyrosine kinase inhibitor (TKI) lorlatinib led to longer progression-free survival (PFS) and better control and prevention of brain metastases compared to those treated with the ALK TKI crizotinib. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

May 31, 2024

A new study found asciminib to be a potentially safer and more effective treatment option for people with newly diagnosed chronic myeloid leukemia (CML) when compared to current standard treatments with tyrosine kinase inhibitors (TKIs). The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

Pages